Data Exclusivity Remains A Top Issue In U.S. Trade Representative's 2011 Special 301 Report
This article was originally published in PharmAsia News
Executive Summary
The failure of U.S. trading partners to adequately protect pharmaceutical test data remains one of the top concerns of the United States Trade Representative in its 2011 Special 301 Report on intellectual property rights